Multiple myeloma (MM), a B cell malignancy characterized by clonal proliferation of plasma cells in the bone marrow, remains incurable despite the use of novel and conventional therapies. In this study, we demonstrated MM cell cytotoxicity triggered by realgar (REA; As 4 S 4 ) nanoparticles (NREA) versus Arsenic trioxide (ATO) against MM cell lines and patient cells. Both NREA and ATO showed in vivo anti-MM activity, resulting in significantly decreased tumour burden. The anti-MM activity of NREA and ATO is associated with apoptosis, evidenced by DNA fragmentation, depletion of mitochondrial membrane potential, cleavage of caspases and antiapoptotic proteins. NREA induced G 2 /M cell cycle arrest and modulation of cyclin B1, p53 (TP53), p21 (CDKN1A), Puma (BBC3) and Wee-1 (WEE1). Moreover, NREA induced modulation of key regulatory molecules in MM pathogenesis including JNK activation, c-Myc (MYC), BRD4, and histones. Importantly, NREA, but not ATO, significantly depleted the proportion and clonogenicity of the MM stem-like side population, even in the context of the bone marrow stromal cells. Finally, our study showed that both NREA and ATO triggered synergistic anti-MM activity when combined with lenalidomide or melphalan. Taken together, the anti-MM activity of NREA was more potent compared to ATO, providing the preclinical framework for clinical trials to improve patient outcome in MM.
Summary
Multiple myeloma (MM), a B cell malignancy characterized by clonal proliferation of plasma cells in the bone marrow, remains incurable despite the use of novel and conventional therapies. In this study, we demonstrated MM cell cytotoxicity triggered by realgar (REA; As 4 S 4 ) nanoparticles (NREA) versus Arsenic trioxide (ATO) against MM cell lines and patient cells. Both NREA and ATO showed in vivo anti-MM activity, resulting in significantly decreased tumour burden. The anti-MM activity of NREA and ATO is associated with apoptosis, evidenced by DNA fragmentation, depletion of mitochondrial membrane potential, cleavage of caspases and antiapoptotic proteins. NREA induced G 2 /M cell cycle arrest and modulation of cyclin B1, p53 (TP53), p21 (CDKN1A), Puma (BBC3) and Wee-1 (WEE1). Moreover, NREA induced modulation of key regulatory molecules in MM pathogenesis including JNK activation, c-Myc (MYC), BRD4, and histones. Importantly, NREA, but not ATO, significantly depleted the proportion and clonogenicity of the MM stem-like side population, even in the context of the bone marrow stromal cells. Finally, our study showed that both NREA and ATO triggered synergistic anti-MM activity when combined with lenalidomide or melphalan. Taken together, the anti-MM activity of NREA was more potent compared to ATO, providing the preclinical framework for clinical trials to improve patient outcome in MM.
Keywords: arsenic compounds, ATO, multiple myeloma, realgar nanoparticles, stem-like side population.
Multiple myeloma (MM) is the second most common haematological malignancy worldwide and is characterized by clonal proliferation of plasma cells in the bone marrow (BM). Moreover, it is defined by high levels of monoclonal protein in serum and/or urine as well as BM plasmacytosis, and is associated with bone lesions, anaemia, cytopenia, hypercalcaemia, peripheral neuropathy, and/or renal dysfunction (Anderson, 2016) . High dose therapy [melphalan (MEL)] followed by autologous stem cell transplantation, as well as novel therapies including immunomodulatory drugs [IMiDs; thalidomide, lenalidomide (LEN) and pomalidomide], proteasome inhibitors [bortezomib (BTZ), carfilzomib and ixazomib], monoclonal antibodies (elotuzumab and daratumumab), and the histone deacetylase inhibitor, panobinostat, have markedly improved clinical outcome of MM patients (Attal et al, 2017) . However, relapse of MM is common, and there remains a need for novel therapies.
In phase II clinical trials in patients with relapsed and refractory MM, Arsenic trioxide (ATO, As 2 O 3 ) shows only modest activity compared to BTZ and LEN (Hussein et al, 2004; Rousselot et al, 2004a) . However, phase I/II clinical trials demonstrate synergism of ATO in combination with ascorbic acid (AA) and MEL (Qazilbash et al, 2008) , with AA and dexamethasone (DEX; Abou-Jawde et al, 2006; Wu et al, 2006) , as well as with AA and BTZ (Berenson et al, 2007) . Moreover, the combination of BTZ with high dose MEL, ATO and AA also shows efficacy in a randomized phase II clinical trial in patients with relapsed/refractory MM research paper First published online 19 October 2017 doi: 10.1111/bjh.14974 (Sharma et al, 2012) . Importantly, ATO is approved for the treatment of relapsed or refractory acute promyelocytic leukaemia (APL) based upon cure of APL patients and favourable toxicity profile (Soignet et al, 1998 (Soignet et al, , 2001 . ATO stimulates differentiation (Chen et al, 1996) , activation of different apoptosis pathways (Liu et al, 2003; McCaffertyGrad et al, 2003; Morales et al, 2008) and autophagy (Lau et al, 2013) , and modulation of signal transduction proteins (Wen et al, 2008) and regulatory molecules (Li et al, 2002; Chou et al, 2005; Mathieu & Besancon, 2006; Morales et al, 2009) . Moreover, ATO combined with ATRA eradicates APL-initiating cells through PML-RARΑ degradation (Nasr et al, 2008) . In addition, ATO inhibits the Notch pathway (Zhen et al, 2010) , antagonizes the Hedgehog pathway through reduction of Gli transcriptional effector (Kim et al, 2010) , and also represses NFjB (Mathieu & Besancon, 2006) and b-catenin (Yu et al, 2007) , thereby facilitating depletion of the cancer stem-like cell population. However, the precise mechanism of arsenic treatment in MM remains largely unknown.
The clinical success of ATO in APL and early promising data in MM prompted us to explore another arsenic compound Arsenic sulfide [realgar (REA); As 4 S 4 ]. Single agent REA achieved a high complete remission rate, prolonged disease-free survival, and tolerable side effects when used as both induction and maintenance therapy in patients with APL (Lu et al, 2002) . Moreover, REA, alone and in combination with imatinib, induced apoptosis and BCR-ABL1 degradation in chronic myeloid leukaemia (CML) models, both in vitro and in vivo (Zhang et al, 2009; Mao et al, 2010) . However, REA is almost insoluble in aqueous solution at neutral and slightly acidic conditions (Balaz & Sedlak, 2010) . To overcome its limited solubility and to increase its bioavailability, nanoparticles of REA (NREA) have been prepared by high-energy milling and applied in nano-sized dimensions (diameter less than 150 nm). Preclinical studies show that NREA (<150 nm nanoparticles) demonstrate higher anti-cancer activity, although the mechanisms of action are not yet defined (Wang et al, 2008b; Pastorek et al, 2014) .
In this study, we demonstrate the MM cytotoxic effects of arsenic prepared by milling into NREA, used in traditional Chinese medicine and associated with greater efficacy, a less genotoxicity, and better tolerability compared to ATO. NREA triggered apoptosis in MM cell lines, both sensitive and resistant to conventional and novel anti-MM agents, as well as patient MM cells in vitro. The mechanisms of anti-MM activity of NREA versus ATO include (i) more pronounced induction of apoptosis [hallmarked by cleavage of caspases (-3, -8, -9 and -12) and downregulation of antiapoptotic molecules and Bcl-2(BCL2)] and decreased mitochondrial membrane potential] (ii) accumulation of G 2 /M cells, followed by up-regulation of cyclin B1, p53 (TP53), p21(CDKN1A), Puma (BBC3) and Wee-1 (WEE1), (iii) modulation of c-Myc (MYC) and BRD4 expression, and activation and upregulation of histones H3 and H2AX (H2AFX), and (iv) depletion of MM the stemlike side population (SP) fraction and clonogenicity of SP cells, either alone or in co-culture with bone marrow stromal cells (BMSC) in vitro. Both NREA and ATO synergistically augment the in vitro anti-MM activity of LEN and MEL. Furthermore, in vivo anti-MM activity of NREA is greater than ATO in xenograft and MM patient-derived human BM-like scaffold (huBMsc) mouse models. This preclinical study provides the rationale for clinical trials of NREA to improve patient outcome in MM.
Design, Material and Methods

Reagents
The arsenic sulfide (realgar, As 4 S 4 ) nanosuspension, NREA, was prepared in a laboratory circulation mill MiniCer (Netzsch, Germany). Five grams of arsenic sulfide (95%, SigmaAldrich St. Louis, MO, USA) were subjected to milling in the presence of 300 ml of 0Á5% polyvinylpyrrolidone (PVP) solution as a nonionic stabilizer for 120 min at a milling speed of 2240 g. The mill was loaded with yttrium-stabilized ZrO 2 milling balls (diameter 0Á6 mm). The resulting nanoparticle suspension was filtered through a 0Á22 lm sterile filter, then tested and stored at 4°C. The particle size distribution was measured by photon cross-correlation spectroscopy using a Nanophox particle size analyser (Sympatec GmbH, Clausthal-Zellerfeld, Germany). The particle size distribution of the certificated standard (Sigma-Aldrich), with mean particle size 950 = 210 nm ( Figure S1A ), was used as control to NREA nanoparticles. The particle size distribution of NREA suspension achieved <150 nm, with mean particle size x 50 = 131 nm ( Figure S1B ). Arsenic trioxide (ATO, As 2 O 3 ) was purchased from Sigma-Aldrich. Stock solutions of ATO (99Á5%) were dissolved in 1% NaOH and titrated to pH 7Á2 with 1% HCl. BTZ (Velcade) and LEN (CC5013) were obtained from Selleck Chemicals (Houston, TX, USA). DEX, MEL, doxorubicin (DOX) and suberoylanilide hydroxamic acid (SAHA, Vorinostat) were obtained from Sigma-Aldrich.
Primary cells and cell lines
A panel of MM cell lines (RPMI 8226-S, also referred to as RPMI-S); RPMI-Dox40 (DOX resistant), RPMI-LR5 (MEL resistant), RPMI-MR20 (mitoxantrone resistant), MM.1S, MM.1R (DEX resistant), OPM-1, OPM-2, KMS-11, KMS-18, OCIMY5, U266 and NCI-H929 and the human BMSC line HS-5 were obtained from American Type Culture Collection (Manassas, VA). All MM cell lines and the human stromal cell line HS-5 were cultured in RPMI 1640 medium (Cellgro, Mediatech, VA) and Dulbecco's modified Eagle medium (DMEM; Cellgro, Mediatech, VA) supplemented with 10% heat-inactivated fetal bovine serum (FBS; Harlan, Indianapolis, IN), 100 u/ml penicillin, 100 lg/ml streptomycin 
Drug sensitivity of cell-based assays
The effect of NREA versus ATO on MM cells was evaluated using the following assays: viability assessment with colourimetric survival 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) assay and luminescent CellTiterGlo (CTG) assay; colony-forming cell (CFC) assay for clonogenic potential; annexin V-fluorescein isothiocyanate assay for quantification of apoptosis; assessment of mitochondrial membrane potential by flow cytometric analysis using the JC-1 fluorescent probe; and flow cytometric analysis of DNA content of nuclei labelled with propidum iodide (PI) for evaluation of cell cycle changes. Detailed information on these assays is included in the Data S1.
Molecular profiling analyses and functional assays
The molecular sequelae of NREA versus ATO treatment in MM cells were evaluated by Western immunoblotting analyses, as described in Data S1. The functional Hoechst 33342 assay was used to assess impact of NREA versus ATO on the stem cell-like SP, either alone or in co-culture model with BMSC HS-5 cells, by labeling of MM cells with carboxyfluorescein diacetate succinimidyl ester (CFSE), according to manufacturer's instructions and detailed in the Data S1.
Tumour cell implantation in mouse models
In vivo experiments of xenograft and MM patient-derived huBMsc mouse models were performed in accordance with the institutional guidelines and under auspices of approved protocols; details are included in the Data S1. All in vivo experiments were approved by the Dana-Farber Cancer Institute Animal Care and Use Committee.
Statistical analysis
The statistical significance of differences in drug-treated versus control cultures was determined using Student's t test. Data are presented as mean AE standard deviation. The minimal level of significance was P < 0Á05. 
Apoptotic features of NREA-versus ATO-treated MM cells
We next assessed whether reduced survival of MM cells triggered by NREA and ATO is due to induction of apoptosis. Annexin V/PI staining and flow cytometric analysis revealed that NREA (0Á5, 1 and 2 lmol/l; for 48 h) induced significant apoptosis in both MM.1S and RPMI-S cells in a dosedependent manner, with early apoptosis evidenced by increased percentage of Annexin V + /PI À cells and late apoptosis by Annexin V + /PI +/À cells; followed by increased percentage of necrosis, evidenced by increased percentage of Annexin V + /PI + cells (Fig 2A) . ATO triggered more modest early and late apoptosis in MM.1S and RPMI-S cells ( Fig 2B) . Early/late apoptotic populations, as well as significant necrosis, were also observed in NREA-treated OPM-1, KMS-11, and OCIMY5 cells ( Figure S3A ), with less pronounced apoptosis/necrosis triggered by ATO ( Figure S3B ). To assess any decrease of mitochondrial membrane potential, a hallmark of apoptosis, staining with the fluorescent lipophilic cation JC-1 dye and flow cytometric analysis was utilized. Significant concentration-dependent decrease of mitochondrial membrane potential, reflected by the elevated levels of JC-1 monomers, was observed in NREA-treated MM cells (Fig 2C) . Of note, NREA triggered more significant decreased mitochondrial membrane potential than ATO ( Fig 2D) . In addition, a dose-dependent significant decrease of mitochondrial membrane potential was detected in OPM-1, KMS-11, and OCIMY5 MM cell lines exposed to NREA or ATO ( Figure S3D ).
Western immunoblotting analysis revealed dose-dependent cleavage of caspase-3, caspase-8 and significant decrease of caspase-9 and caspase-12 in MM.1S cells treated with NREA ( Fig 2E) . Similarly, significant cleavage of caspase-3 was observed in NREA-treated RPMI-S cells (Fig 2F) . In addition, ATO-treated MM cell lines (MM.1S and RPMI-S) revealed less pronounced cleavage of caspase 3 and caspase 8, and no decrease of caspase 9. No significant changes in Heat shock protein 70 expression were observed in NREA-treated MM.1S cells, except for a slight decrease at the highest concentrations. A modest downregulation of the anti-apoptotic protein Mcl-1 (MCL1), with significant upregulation of dye, and analysed with a FACS Canto II flow cytometer. The increased level of JC1 monomers reflects decreased mitochondrial membrane potential. Three independent experiments were performed, and means AE standard error are presented. (E) MM.1S and (F) RPMI-S cells were cultured with NREA (0Á5, 1 and 2 lmol/l) or ATO (0Á5, 1 and 2 lmol/l) for 48 h. Western blot analyses were performed in whole cell lysates (20 lg of proteins/lane) using anti-caspase-3 (Casp-3), -caspase-8 (Casp-8), caspase-9 (Casp-9), caspase-12 (Casp-12), -Hsp70, -Mcl-1, -Bcl-2, and -Bax. GAPDH served as a loading control. Results are representative of two independent experiments. ATO, arsenic trioxide (As 2 0 3 ); MM, multiple myeloma; NREA, realgar (As 4 S 4 ) nanoparticles; PI, propidium iodide.
Mcl-1 spliced variants, was triggered by NREA or ATO in both MM cell lines. A slight down-regulation of Bcl-2 (BCL2) protein in response to NREA treatment was noted in MM.1S cells, whereas increase of pro-apoptotic Bax protein after treatment was observed in RPMI-S cells; in contrast, no similar changes were observed after ATO treatment. Overall, our data indicate that NREA induces more potent anti-MM activity than ATO, associated with induction of apoptotic cell death, downregulation of mitochondrial transmembrane potential, and modulation of caspases and anti-apoptotic molecules.
G 2 /M phase accumulation of NREA-versus ATOtreated MM cells
The cell cycle profile of NREA-versus ATO-treated MM cell lines was next evaluated by flow cytometric analysis. Treatment of MM.1S and RPMI-S cells with NREA (0Á5, 1 and 2 lmol/l for 24 h) increased the percentage of cells in G 2 /M phases (significantly greater in MM.1S), associated with decreased S and G 0 /G 1 phases, followed by an increase in sub G 1 population (Fig 3A) . A less pronounced effect on cell cycle profile was observed in ATO-treated MM.1S cells, and no such changes were noted in RPMI-S cells (Fig 3B) . NREA and ATO treatment triggered concentration-dependent increases in G 2 /M phase in OPM-1, OCIMY5, and KMS-11 cells (also G 0 / G 1 arrest in KMS-11 cells), NREA to a greater extent than ATO ( Figure S4A, B) . In addition, immunoblotting analyses revealed significantly greater increase of cell cycle G 2 /M regulator cyclin B1 after NREA than ATO treatment of MM.1S and RPMI-S cells, without associated change in checkpoint kinase 2 (Chk2, CHEK2) (Fig 3C, D) . Importantly, c-Myc protein was significantly downregulated after NREA treatment in both MM cell lines. Wee-1 protein revealed profound concentration-dependent cleavage triggered by NREA and ATO. Furthermore, other cell cycle regulatory signalling molecules, including p53, p21, Puma (mostly in lower concentrations), phosphorylated-histone H3 (p-H3), histone H3 (H3), phosphorylated-histone H2AX (p-H2AX), and histone H2AX (H2AX), were significantly upregulated, more pronounced in NREA-compared to ATO-treated MM cells. Overall, the anti-MM effect of NREA was accompanied by accumulation of cells in G 2 /M cell cycle arrest, with associated up-regulation of cell cycle regulatory molecules.
Molecular targets of NREA-versus ATO-treated MM cells
To determine modulation of key regulatory molecules and transcriptional factors in NREA-versus ATO-treated MM cells, both MM.1S (Fig 4A) and RPMI-S cells ( Fig 4B) were treated with NREA or ATO (0Á5, 1 and 2 lmol/l) for 8 h. Both drug treatments did not show any significant activation of p-GSK3ab kinase. Interestingly NREA, to a greater extent than ATO, triggered marked activation (phosphorylation) of JNK, followed by significant degradation of total JNK in both MM cell lines. In contrast, there were no significant changes in p38 (MAPK14) and Akt proteins in MM cells treated with either NREA or ATO. Early downregulation of c-Myc by NREA treatment was detected at 8 h, suggesting c-Myc as a primary target of NREA. In addition, NREA treatment also induced marked BRD4 degradation in MM.1S cells. We also observed dose-dependent activation of p-H3 and p-H2AX, followed by significant upregulation of total H3 and H2AX, in NREA-and ATO-treated MM cells. Moreover, early degradation of HDAC-6 and 4EBP-1 was found in MM.1S cells treated with NREA at high concentration. In contrast, NREA or ATO did not trigger any significant changes in 14-3-3 and IRF4 proteins in both MM cell lines. Taken together, our data therefore suggest that NREA treatment modulates expression of several transcription/signalling molecules with key regulatory roles in MM pathophysiology including cMyc, BRD4, histones (H3 and H2AX), HDACs6 and 4EBP-1, to a greater extent than ATO.
Decrease of SP cells and its clonogenic potential by NREA versus ATO-treated MM cells
To determine the effect of NREA and ATO on the stem celllike SP phenotype of MM cells (Jakubikova et al, 2011a) , we next treated MM cells (with high proportion of SP fraction) with sublethal concentrations of NREA and ATO for 72 h. To evaluate SP cell fraction, flow analysis of MM cells for low intracellular content of Hoechst 33342 dye revealed that NREA significantly decreased the proportion of SP cells in MM cells in a dose-dependent manner (Fig 5A) , whereas no significant differences in SP fraction were observed in ATOtreated cells (Fig 5B) . To evaluate the effect of the BM microenvironment, MM cells were cultured in the absence and presence of BMSCs, and then analysed for SP cell fraction by low intracellular accumulation of Hoechst 33342 dye. Treatment by NREA, but not ATO, significantly depleted SP cells in co-cultures MM cells with BMSCs. Furthermore, our previous study confirmed the clonogenic and tumourigenic potential of SP cells (Jakubikova et al, 2011a) . To evaluate the effect of NREA and ATO on the clonogenic potential of SP cells, we next seeded MM cells with a high proportion of SP cells on methylcellulose, treated with NREA and ATO at concentrations, which eliminated the SP fraction (NREA) for each MM cell line, and assessed the number of colonies at day 14. The clonogenic potential of SP cells was significantly decreased by NREA, but not by ATO, treatment (Fig 5C) , as shown in representative colony-forming unit/clonogenic assays (Fig 5D) .
In vivo activity of NREA versus ATO against MM cells tumour-bearing mice were treated intraperitoneally with NREA (2Á5, 5 and 7Á5 mg/kg), ATO (2Á5, 5 and 7Á5 mg/kg) or with the respective vehicle in xenograft MM mouse model. Treatment with NREA triggered more significant tumour growth inhibition than ATO from day 5 of treatment until the end of the treatment (P < 0Á001 for all comparisons, ShapiroWilk Normality Test) (Fig 6A) . Importantly, NREA and ATO treatment caused no significant changes in weight compared to vehicle-treated control mice (Fig 6B) .
To confirm in vivo anti-MM activity of NREA, huBMscmice were inoculated with primary MM cells (CD138 + ) from a relapsed/refractory MM patient (Groen et al, 2012) , and then tumour-bearing mice were intraperitoneally treated with NREA (5 mg/kg) or with the respective control (vehicle). NREA treatment significantly reduced tumour volumes (3-fold) compared to control mice (Fig 6C , P < 0Á001, control versus NREA treatment), resulting in significantly lower tumour volumes (Fig 6D) . These results suggest that NREA treatment reduced tumour growth to a greater extent than treatment with ATO, and was well tolerated in both (xenograft and patient-derived huBMsc) myeloma mouse models. 
NREA versus ATO combinations with novel and conventional anti-MM therapies
To evaluate combinations of NREA or ATO with anti-MM agents, MM.1S, RPMI-S, and OPM-1 cells were treated with combined NREA or ATO with novel anti-MM agents LEN, BTZ or SAHA, as well as with the conventional anti-MM agents DEX, DOX or MEL (Fig 7, S4) . The anti-MM activity of combined treatment was analysed at 48 h by MTT assay. Synergistic effects were assessed using CalcuSyn software; fractions affected (Fa) in heatmaps and combination indices (CI) for each combination therapy are presented in isobologram graphs. We observed enhanced killing with LEN and NREA at all drug doses, with CI < 1 for the majority of conditions, except for OPM-1 cells where additive effects were detected (Fig 7A) . Similar data were observed when NREA was combined with MEL ( Fig 7B) . In addition, NREA showed more potent synergistic activity when combined with either LEN or MEL compared to ATO. In contrast, we observed that both NREA and ATO generated moderate antagonism/additive effects when combined with BTZ, except for moderate synergistic cytotoxicity of the combinations in OPM-1 cells ( Figure S5A ). Furthermore, NREA in combination with DOX or DEX were antagonistic in MM.1S and OPM-1 cells; in contrast, ATO in combination with DEX showed moderate synergism in MM.1S and OPM-1 cells and, when combined with DOX, demonstrated moderate synergism in RPMI-S cells ( Figure S5B, C) . Similar effects were observed in combination with SAHA: NREA combinations showed moderate antagonistic/additive effects, while SAHA in combination with ATO showed synergistic effects ( Figure S5D ). In summary, these data demonstrate the synergistic MM cytotoxicity when NREA was combined with LEN or MEL, whereas antagonistic effects were observed when NREA was combined with BTZ, DOX, DEX and SAHA.
Discussion
Arsenic has been used in ancient medicine for several centuries to treat a variety of ailments including ulcers, plague and malaria (Waxman & Anderson, 2001 ). In late 1800s, arsenite had been reported to have an anti-leukaemic effect and was used as leukaemic treatment until it was replaced by busulfan in the mid-1900s (Kwong & Todd, 1997; Balaz & Sedlak, 2010) . In the modern era, active ingredients of Anti-MM Activity of NREA Versus ATO ª 2017 John Wiley & Sons Ltd arsenic, including orpiment (As 2 S 3 ), realgar (As 4 S 4 ), and arsenolite-arsenic trioxide (As 2 O 3 ), have been evaluated for the treatment of various cancers including acute promyelocytic leukaemia (APL), myelodysplastic syndrome, and MM (Soignet et al, 2001; Hussein et al, 2004; Rousselot et al, 2004a; Schiller et al, 2006) . Several multicentre clinical trials provided support for the approval of ATO to treat patients with APL who either failed to respond to or relapsed following all-trans-retinoic acid (ATRA) and anthracycline-based chemotherapy (Soignet et al, 1998 (Soignet et al, , 2001 ). Most importantly, including ATO in standard front-line therapy achieves high response rates and improves survival in patients with APL (Mathews et al, 2010; Leech et al, 2015) . Furthermore, realgar (REA) as a single agent achieves high complete remission rates, long disease-free survival and tolerable side effects when used in both induction and maintenance therapy for APL (Lu et al, 2002) . In addition, ATO has also shown efficacy in other haematological malignancies, including MM, myelodysplastic syndrome (MDS), acute myeloid leukaemia, and adult T-cell leukaemia/lymphoma, as well as in solid tumours, including bladder cancer, glioma, breast cancer, renal cell cancer, hepatocellular carcinoma and others (Schiller et al, 2006; Emadi & Gore, 2010) .
Initial clinical studies of ATO as a single agent in heavily pre-treated relapsed or refractory MM demonstrated only limited responses compared to BTZ and LEN (Hussein et al, 2004; Rousselot et al, 2004a) . A phase I/II trial demonstrated that ATO in combination with AA shows clinical activity ; with higher proportion of SP cells) were seeded on methylcellulose, and then, treated with NREA and ATO. Number of RPMI-S cells colonies after treatment with NREA (0Á5 lmol/l) and ATO (1 lmol/l); OPM-1 colonies after treatment with NREA (0Á25 lmol/l) and ATO (0Á5 lmol/l); KMS-11colonies after treatment with NREA (0Á1 lmol/l) and ATO (0Á2 lmol/l); and OCIMY5 colonies after treatment with NREA (0Á25 lmol/l) and ATO (0Á5 lmol/l) and compared to respective control (untreated) cells at day 14. (D) Representative images of MM cell colonies, control (untreated) and treated by NREA and ATO, were obtained using a Leica inverted microscope (with a Leica DFC300 Fx camera [10-20 9 /0Á1]; and processed using Leica IM50 image-acquisition software Version 4) at day 14. Results are representative of two independent experiments. ATO, arsenic trioxide (As 2 0 3 ); BMSC, bone marrow stromal cells; MM, multiple myeloma; NREA, realgar (As 4 S 4 ) nanoparticles; SP, side population. [Colour figure can be viewed at wileyonlinelibrary.com] and tolerability, providing the rationale for future trials in combination with other therapies (Bahlis et al, 2002) . Similarly, synergism of ATO was observed in combination with AA and MEL (Qazilbash et al, 2008) , with AA and DEX (Wu et al, 2006) as well as with AA and BTZ (Berenson et al, 2007) . Recently, randomized phase II clinical trials showed that the combination of BTZ with high dose MEL, ATO, and AA achieved responses in relapsed/refractory MM (Sharma et al, 2012) .
ATO has been regarded as a toxic compound that is associated with adverse side effects with long-term use. Most clinical trials found that ATO has a limited role in the treatment of MM due to toxicity and less efficacy compared with other novel agents. However, it is now clearly understood that the toxicity of arsenic is highly dependent on methylation status and valence state. In man, most inorganic arsenic is converted to methylated metabolites by sequential reduction, oxidation and methylation reactions (Cohen et al, 2006) . Realgar (REA; As 4 S 4 ) might therefore exhibit less toxicity and better tolerability than ATO (Balaz & Sedlak, 2010) , suggesting its promise as a potential novel therapy. To date, the metabolism and resulting metabolites of REA in man is not fully delineated. REA is poorly soluble in aqueous and most organic solvents due to its high intrinsic lattice energy, limiting its clinical utility. However, modification of water insoluble drugs (like REA) into ultrafine particles, thereby increasing surface area by one or more order(s) of magnitude, can increase the dissolution rate (Kesisoglou et al, 2007) and improve bioavailability. Furthermore, tumour vasculature is highly abnormal, proliferative, activated and tortuous; it has increased permeability and gaps, with pores between 350 and 800 nm in diameter, with a cut-off around 400 nm (Balaz & Sedlak, 2010) . Thus, preparation of nanoparticles of 100-200 nm in 6 cells in 200 ll PBS) were injected SC into CB17/SCID mice, and treatment was started when tumours became palpable. Tumour-bearing mice were randomly allocated into seven groups (six mice per group) treated with: vehicle (0Á2 ml 0Á5% PVP) only (control), NREA (2Á5, 5 and 7Á5 mg/ kg), and ATO (2Á5, 5 and 7Á5 mg/kg) intraperitoneally every day for 5 days a week. Tumour diameters were measured every 2-3 days with caliper, and tumour volumes were calculated according to the formula of the volume of an ellipse: V = 4/3p 9 (a/2) 9 (b/2) 2 , where a and b corresponds to the longest and shortest diameters of the tumour, respectively. Both NREA and ATO significantly inhibited tumour growth (P =< 0Á001; by Normality Test (Shapiro-Wilk)). Data are presented as the mean of data AE SEM (n = 6) (*P < 0Á001 compared with control and treatment). (B) Mice weights were measured every 2-3 days and compared among NREA-and ATO-treated versus vehicle-treated control mice. (C) In the human bone marrow-like scaffold (huBMsc) based-model of patient MM cells, patient MM (CD138 + ) cells (2-3 9 10 6 cells in 200 ll PBS) were injected SC into implanted scaffold loaded with human mesenchymal stem cells (MSCs; 14 days prior the implantation) in NSG mice. Treatment was started when tumours became visible. Tumour-bearing mice were randomly allocated into two groups (six mice per group) treated with: vehicle (0Á2 ml 0Á5% polyvinylpyrrolidone) only (control); and NREA (5 mg/kg) intraperitoneally every day for 5 days a week. Caliper measurements of tumour diameters were done at the end of the experiment. Tumour volumes were calculated according to the formula of the volume of an ellipse: V = 4/3p 9 (a/2) 9 (b/2) 2 , where a and b corresponds to the longest and shortest diameters of the tumour, respectively. NREA significantly reduced tumour volumes (P =< 0Á001, Shapiro-Wilk Normality Test). Data are presented as the mean AE SEM (n = 6) (*P < 0Á001 compared with control and NREA treatment). (D) Photographs using camera IVIS 1327 in the Xenogen system show representative vehicle-treated tumours (upper panel) and NREA-treated tumours (lower panel). ATO, arsenic trioxide (As 2 0 3 ); NREA, realgar (As 4 S 4 ) nanoparticles.
Anti-MM Activity of NREA Versus ATO ª 2017 John Wiley & Sons Ltd diameter by any nanosizing technique facilitates nano-drug penetration into a tumour body. Importantly, recent advances in milling technology have enabled the production of such nanoparticles in a reproducible manner. Specifically, nanocrystalline dispersions are prepared using the media milling processes (Merisko-Liversidge & Liversidge, 2011), which readily fractures micron-sized drug crystals into homogeneous nanoparticle dispersions. To overcome low solubility and the limited bioavailability manifested by the increase of the total arsenic content in the urinary excretion (Wu & Ho, 2009) , we have in this study prepared REA nanoparticles (NREA) of less than 150 nm diameter by high-energy milling; this is critical because NREA that are less than 150 nm in size have greater anti-cancer efficacy (10, 25, and 50 lmol/l) or MEL (2Á5, 5 and 10 lmol/l) for 48 h. Cell viability was then assessed using the MTT assay. Fractions-affected (Fa -ratio of number of nonviable MM cells/total number of MM cells) calculated according to the Chou-Talalay method was visualized in a colour-coded format and compared to treatment with each drug alone. Isobologram analysis (by Calcusyn software according to the Chou-Talalay method) was performed to calculate the combination index (CI) for each combination. The x-axis corresponds to the fractional effect at various combination doses and the y-axis represents the CI; CI < 1 indicates drug synergy, whereas CI = 1 is considered additive, and CI > 1 indicates antagonism. Data represent mean (AESD) of triplicate cultures. ATO, arsenic trioxide (As203); LEN, lenalidomide; MEL, melphalan; NREA, realgar (As4S4) nanoparticles.
than larger particles in several preclinical cancer models (Wang et al, 2008b; Pastorek et al, 2014) .
In this study, we have evaluated the cytotoxic effect of arsenic in the form of NREA and compared it with ATO administration in MM. Both NREA and ATO showed significant dose-dependent activity against various MM cell lines, either sensitive or resistant to conventional and novel anti-MM therapies. Importantly, NREA was 2-4 times more potent than ATO against all MM cell lines tested. EC 50 values of NREA against patient MM cells were in the range 0Á32-3 lmol/l, profoundly lower than on normal MNCs; in contrast ATO treatment showed significantly higher EC 50 values (up to 8Á4 lmol/l) against both patient MM cells and normal MNCs. Moreover, the tumour microenvironment plays an important role in MM progression and malignant plasma cells also influence their tumour microenvironment or vice versa. In response to both NREA and ATO, MM microenvironment cells (non-MM) were significantly more resistant (2-4 times) compared to CD138 + MM plasma cells. Similar to our data, a previous study also shows induction of cell death/apoptosis of patient MM cells by ATO (5 lmol/l, but not 2 lmol/l) (Rebersek et al, 2014) . Our data therefore suggest a favourable therapeutic window for NREA, given that NREA doses of 0Á2-3 lmol/l are active against all tested MM cell lines and patient cells in vitro, without effect on healthy cells. Moreover, ATO-treatment significantly reduces in vivo human MM cell growth and is well tolerated in mouse xenograft models (Rousselot et al, 2004b) . REA similarly shows significant in vivo anti-cancer effects through BCR-ABL1 degradation in a CML mouse model (Mao et al, 2010) , as well as in SCID mice transplanted with human APL-ascites (Wang et al, 2008a) . In addition, in vivo NREA administration is effective in the treatment of melanoma model . In this study, in vivo experiments showed that NREA treatment more significantly decreased MM burden than ATO in xenograft (MM cell lines-derived); and confirmed in MM patient-derived huBMsc mouse models, indicating significant in vivo anti-MM activity of NREA. Our mechanistic studies showed that the anti-MM activity of NREA and ATO is due to induction of apoptosis and cell cycle arrest. It has previously been reported that ATO induces both intrinsic and extrinsic apoptotic pathways (Wu et al, 2010) with activation of caspase-dependent (such as caspase-3 and -9) or caspase-independent pathways (Liu et al, 2003; McCafferty-Grad et al, 2003) , followed by upregulation of pro-apoptotic BH3-only proteins (Noxa [PMAIP1], BMF, and Puma [BBC3] ) and downregulation of anti-apoptotic proteins Mcl-1 and Bcl-XL (BCL2L1) (Morales et al, 2008) . Furthermore, ATO rapidly targets the mitochondria through Apo2/TRAIL (TNFRSF10A/TNFSF10), activation of caspase-8, cleavage of BID, decreased mitochondrial membrane potential, and release of AIF (AIFM1) from mitochondria in a Bcl-2 independent fashion (Liu et al, 2003) . Our data showed that NREA and ATO triggered MM apoptosis, detected by annexin V/PI staining and DNA fragmentation, and was associated with increased activity of caspases-3, -9 and -12; down-regulation of the anti-apoptotic proteins, Mcl-1 and Bcl-2; as well as upregulation of proapoptotic protein, BAX. The depolarization of mitochondrial membrane potential and cleavage of caspase-8 triggered by both compounds indicates involvement of mitochondria in NREA-and ATO-induced apoptosis in MM. Overall, significantly more pronounced induction of apoptosis was triggered by NREA than ATO. In addition, ATO treatment induces downregulation of c-Myc and phosphorylation of (p)-Rb (p-RB1) and up-regulation of p53, p21 Cip1 (CDKN1A), and p27
Kip1 (CDKN1B), resulting in G 0 /G 1 or G 2 /M cell cycle arrest (Wu et al, 2010) . Our results showed that treatment with NREA induces cell cycle arrest, with accumulation of cells in G 2 /M phase along with increased expression of Cyclin B1; histones H3 and H2AX (as well as their activation); p53 and its targets p21 (cyclin-dependent kinase inhibitor 1); and pro-apoptotic protein Puma (p53 upregulated modulator of apoptosis; also termed BCL2 binding component 3, BBC3); as well as significantly decreased expression of c-Myc (a multifunctional transcription factor that plays a role in cell cycle progression, apoptosis and cellular transformation) and Wee1 (serine/threonine nuclear kinase; a key protein regulator of cell cycle progression by inhibiting entry into mitosis, through inhibiting cyclindependent kinase 1 (Cdk1) implicated in G 2 /M phase of the cell cycle). In preclinical studies, ATO stimulates differentiation (through degradation the PML-RARΑ fusion protein) (Chen et al, 1996) , as well as activation of cell death pathways by intrinsic (Morales et al, 2008) or extrinsic apoptosis (Liu et al, 2003) and autophagy (Lau et al, 2013) . Moreover, ATO activates signal transduction proteins (JNK and p38) (Wen et al, 2008) , downregulates extracellular surface molecules (Notch receptor and the Notch ligand JAG2) (Hu et al, 2013) , and upregulates defence mechanisms [reactive oxygen species (ROS) and glutathione (GSH) level] (Matulis et al, 2012) . Our data showed that NREA treatment in MM triggered more pronounced activation of JNK than ATO, followed by degradation of total JNK protein. In addition, numerous intracellular molecules are modulated by ATO including: histone H3 phosphoacetylation (Li et al, 2002) ; increased Nrf-2 (Morales et al, 2009 ); suppression of hTERT, C17, and MYC through Sp1 oxidation (Chou et al, 2005) ; repression of NFjB activation (Mathieu & Besancon, 2006) ; downregulation of the WT1 gene (Chen et al, 2011) ; as well as blockade of autophagic flux, resulting in the accumulation of p62 and sequestration of Keap1 (Lau et al, 2013) . The effect of NREA on cell signalling pathways may differ, because it induces less oxidative DNA damage and is less genotoxic in comparison to ATO. REA treatment increases some genes, including CCL2, CCL3, BTG1, TNFAIP3, TNFAIP8, SLC38A2 and IGFBP4, associated with cell growth, cell-cell signalling, regulation of apoptosis and cell homeostasis (Wang et al, 2006) . Especially in MM, rearrangement or Anti-MM Activity of NREA Versus ATO ª 2017 John Wiley & Sons Ltd translocation of MYC is one of the most common events, resulting in activation of Myc pathway in patient MM cells. MYC transcription is associated with increased histone acetylation, followed by recruitment of acetyl-lysine binding modules or extra-terminal bromodomain proteins, especially BRD4. BRD4 has been shown to mark select M/G1 genes in mitotic chromatin, as a transcriptional memory and to direct post-mitotic transcription. Moreover, BRD4 is strongly enriched at immunoglobulin heavy chain (IGH) enhancers bearing IGH rearrangement at the MYC locus in MM cells (Delmore et al, 2011) . Here we showed significant down-regulation of c-Myc early (8 h) after NREA administration. Moreover, early degradation of BRD4, HDAC6 and 4EBP-1 was also observed. Concentration-dependent activation (phosphorylation) of histones p-H3 and p-H2AX, along with significant up-regulation of H3 and H2AX expression, was detected in response to NREA. In summary, early significant downregulation of c-Myc, BRD4 degradation, and upregulation of histones was triggered by NREA treatment, suggesting that the c-Myc pathway is a primary target of NREA in MM.
MM contains diverse sub-clones, which leads to tumour persistence and re-growth after therapy (Bolli et al, 2014) . Previous studies suggest that MM sub-clones may contain tumour-initiating or cancer stem-like cells (CSC), which maintain growth and proliferation, as well as contribute to drug-resistance (Matsui et al, 2008; Kim et al, 2012; Chaidos et al, 2013) . We confirmed the existence of MM stem-like cells by identifying "side population" (SP) cells within the CD138-positive fraction, an enriched source of tumour-initiating cells with clonogenic and tumourigenic stem cell properties in MM (Jakubikova et al, 2011a) . Moreover, all MM patients relapse due to drug-resistant sub-populations that escape from conventional and novel therapies; therefore, targeting of such populations is critically important. ATO combined with ATRA is a promising regimen for the eradication of leukaemia-initiating cells through PML-RARA degradation in APL (Nasr et al, 2008) . Furthermore, ATO inhibits the Notch pathway (Zhen et al, 2010) ; antagonizes the Hedgehog pathway by preventing ciliary accumulation and reducing stability of the Gli transcriptional effector (Kim et al, 2010) ; and also represses NFjB and b-catenin (Mathieu & Besancon, 2006) , thereby facilitating depletion of CSC. In addition to Oct4, Sox2, and Klf4 transcription factors, c-Myc is not only central in MM pathogenesis, but is also involved in maintenance of stemness. Therefore, we here hypothesized that arsenic targeting of CSC may eliminate the MM stemlike cell population (SP cells). Importantly, NREA treatment significantly depleted cell fraction and clonogenicity of SP cells in MM cells. In contrast, no significant changes in clonogenicity and proportion of SP cells were triggered by ATO at subtoxic concentrations, with slight activity only at higher toxic concentrations (5 lmol/l) of ATO (Du et al, 2015) . Given that the tumour microenvironment, especially BMSCs, provides protection and nourishment for SP cells (Jakubikova et al, 2011a) , we also assessed the effect of the BMSCs on the NREA-and ATO-effect on SP cell phenotype. In our previous study, LEN eliminated MM SP cells alone whereas, in the context of the BM microenvironment, both LEN and thalidomide were active (Jakubikova et al, 2011a) . While ATO was not active, we observed significant decrease of SP cells after treatment with NREA, even in the context of BMSCs, providing the rationale for its clinical evaluation in MM.
Several preclinical studies have shown that ATO in combination with (i) signalling inhibitors, including recombinant mutant human TRAIL (Zhou et al, 2016) , PD184352 (Lunghi et al, 2008) , and sulforaphane (SFN) (Doudican et al, 2012) ; (ii) oxidative stress pathway modulators [such as AA (Bahlis et al, 2002) ]; and (iii) therapeutic drugs [MEL, BTZ , imatinib, 5-azacytidine , valproic acid (Wang & Zhang, 2015) and ATRA] exhibits synergistic anti-MM activity both in vitro and in vivo. Our previous study shows that SFN, a dietary isothiocyanate found in cruciferous vegetables, has anti-MM activity associated with induction of apoptosis (Jakubikova et al, 2011b) . Moreover, SFN synergistically enhances the cytotoxicity of ATO through ROS generation and induction of endoplasmic reticulum stress, ultimately inhibiting protein secretion in MM (Doudican et al, 2012) . Our study showed that conventional anti-MM drugs (MEL, DEX, and moderately DOX) as well as novel agents (LEN and SAHA) greatly enhance ATO-induced cytotoxicity in MM cells. Synergistic cytotoxicity due to ATO with BTZ is associated with augmented STAT3 inhibition and JNK and p38 activation, followed by apoptosis induction Held et al, 2013) ; however, our data showed either antagonistic or additive activity of ATO/BTZ combination. Moreover, REA in combination with imatinib shows significant synergistic effects through induction of apoptosis and suppression of BCR-ABL activity in an in vitro CML model (Zhang et al, 2009) . In this study, we observed that NREA synergistically augmented the in vitro anti-MM activity of LEN and MEL. Combining other anti-MM agents (DEX, DOX, BTZ and SAHA) with NREA showed either antagonistic or additive effects. Overall, our study therefore showed that both NREA and ATO have potent anti-MM activities when combined with LEN or MEL, and that significant synergism is observed when ATO is combined with conventional anti-MM agents.
In summary, we here evaluated the anti-tumour activity of arsenic prepared by milling realgar into nanoparticles (NREA), which has been used in traditional Chinese medicine with greater efficacy, less genotoxicity and better tolerability compared to ATO. Our preclinical study indicates that NREA has more potent anti-MM activities than ATO, with enhanced depletion of MM stem-like SP cells and synergistic anti-MM activity with LEN and MEL, providing the rationale for future clinical evaluation of NREA therapy to improve patient outcome in MM.
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